FOR IMMEDIATE RELEASE
January 27, 2025
Portsmouth, NH – January 27, 2025 — MediSpend, a global technology company providing best-in-class
solutions for the life sciences industry, announces its acquisition of Real Life Sciences (RLS), a leader in
advanced anonymization solutions for clinical trial and other data. MediSpend’s second acquisition in
less than a year reinforces its commitment to expanding its presence and capabilities in the Governance,
Risk and Compliance (GRC) space.
The acquisition of RLS bolsters MediSpend’s ability to support life sciences companies and contract
research organizations (CROs) in navigating complex regulatory requirements to disclose clinical trial
results data while protecting participant privacy and intellectual property. RLS’s flagship platform, RLS
Protect, delivers industry-leading solutions for anonymization and redaction, enabling organizations to
confidently disclose clinical trial data with health authorities, research partners, internal teams and
publications while safeguarding participant privacy and commercially confidential information.
Real Life Sciences’ offerings include:
RLS Protect – Anonymization: Advanced quantitative risk modeling to ensure participant privacy
in shared clinical data and documents. RLS Protect leverages proprietary Natural Language
Processing to accelerate the identification and classification of personal data found within
clinical data
RLS Protect – Redaction: Comprehensive tools for redacting data, including commercially
confidential information from documents in compliance with global regulatory standards
Voluntary Data Sharing: Streamlined sharing of anonymized clinical trial data internally and
externally while accelerating secondary research
Anonymization Services: An expert-driven team delivers anonymization and redaction projects
on time and per health authority guidance, leveraging the RLS Protect proprietary technology
and proven methodologies
“Real Life Sciences’ innovative solutions align perfectly with MediSpend’s mission to empower life
sciences companies with technology that drives growth, compliance and transparency,” said Leigh
Powell, Executive Chairman of MediSpend. “This acquisition expands the company’s reach into research
and development compliance and the protection of vital intellectual property as well as enhances our
ability to serve a broader market and support our clients with tools to meet evolving global regulatory
demands.”
RLS’ solutions address compliance requirements across major regulatory bodies, including EMA (EU)
536/2014, EMA Clinical Data Publication Policy 0070, Health Canada Public Release of Clinical
Information (PRCI), FDA disclosure mandates and more. Their proven track record in securing data
privacy while balancing clinical utility in the data makes them a trusted partner in the life sciences
industry.
Expanding the Scope of Compliance Technology
With the addition of RLS, MediSpend strengthens its portfolio of solutions, enabling clients to manage
compliance and regulations comprehensively from commercial operations to R&D.
“This combination is a transformative milestone in Real Life Sciences’ growth journey,” said Elliot
Zimmerman, CEO of Real Life Sciences. “Becoming a MediSpend company empowers us to further
enhance our solutions for life sciences organizations as they navigate an evolving set of global regulatory
requirements for clinical transparency, data sharing and participant privacy. Together, we are uniquely
positioned to deliver innovative solutions to clients across the life sciences industry.”
About MediSpend
MediSpend’s best-in-class solutions empower life sciences companies to grow their business compliantly
through top-rated solutions and client services. MediSpend provides commercial compliance solutions
for the largest pharmaceutical, medical device and dental companies as well as emerging biotech
companies across the world. MediSpend is headquartered in Portsmouth, N.H., with offices in
Minnesota, New York, Pennsylvania and the Netherlands. Visit MediSpend online
at www.medispend.com.
About Real Life Sciences
Real Life Sciences is a leading provider of advanced anonymization and redaction solutions for clinical
trial data and other sensitive information. Their flagship platform, RLS Protect, enables life sciences
companies and CROs to comply with regulatory requirements while protecting participant privacy and
commercially confidential information. Madison Park Group acted as exclusive financial advisor to Real
Life Sciences on the transaction.
Media Contact
Seth Houston
shouston@medispend.com